38 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
BMY Bristol-Myers Squibb Company $61.3 $100.03B N/A
Article Searches
Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock Right Now http://www.zacks.com/stock/news/420048/why-bristol-myers-squibb-bmy-is-a-great-dividend-stock-right-now?cid=CS-ZC-FT-420048 May 27, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Roche Gets FDA Nod for Expansion of Cobas 6800/8800 Systems http://www.zacks.com/stock/news/419984/roche-gets-fda-nod-for-expansion-of-cobas-6800-8800-systems?cid=CS-ZC-FT-419984 May 27, 2019 - Roche (RHHBY) gets FDA clearance for the expansion of its leading testing menu.
This Just In: Goldman Sachs Picks 4 Big Pharma Stocks to Buy https://www.fool.com/investing/2019/05/28/this-just-in-goldman-sachs-picks-4-big-pharma-stoc.aspx?source=iedfolrf0000001 May 28, 2019 - And the analyst really likes one in particular.
BMY or NVO: Which Is the Better Value Stock Right Now? http://www.zacks.com/stock/news/421291/bmy-or-nvo-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-421291 May 29, 2019 - BMY vs. NVO: Which Stock Is the Better Value Option?
Celgene's Revlimid-Rituximab Combo Gets FDA Nod for Lymphoma http://www.zacks.com/stock/news/421410/celgenes-revlimid-rituximab-combo-gets-fda-nod-for-lymphoma?cid=CS-ZC-FT-421410 May 29, 2019 - Celgene's (CELG) Revlimid in combination with a rituximab product gets FDA approval for the treatment of adult patients with previously treated follicular lymphoma or marginal zone lymphoma.
Roche (RHHBY) Up 6.3% YTD on Strong Demand for New Drugs http://www.zacks.com/stock/news/422851/roche-rhhby-up-63-ytd-on-strong-demand-for-new-drugs?cid=CS-ZC-FT-422851 May 31, 2019 - Roche's (RHHBY) performance has been strong in the year so far, driven by solid growth of Ocrevus, Perjeta, Tecentriq and Hemlibra.
Why Cancer-Fighting Stocks & ETFs Are Soaring http://www.zacks.com/stock/news/424108/why-cancer-fighting-stocks-etfs-are-soaring?cid=CS-ZC-FT-424108 Jun 03, 2019 - The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.
Gilead Presents Data on CAR T Cell Therapy Candidate at ASCO http://www.zacks.com/stock/news/423909/gilead-presents-data-on-car-t-cell-therapy-candidate-at-asco?cid=CS-ZC-FT-423909 Jun 03, 2019 - Gilead (GILD) presents data from a phase I study on experimental CAR T cell therapy, KTE-X19, at ASCO and announces collaboration with Humanigen.
Roche Presents Positive Data on Xolair & Updates From ASCO http://www.zacks.com/stock/news/423876/roche-presents-positive-data-on-xolair-updates-from-asco?cid=CS-ZC-FT-423876 Jun 03, 2019 - Roche (RHHBY) reports positive data from late-stage studies on allergic asthma drug, Xolair, for a new indication, and additional results on Tecentriq and Avastin combo at ASCO.
Merck's Keytruda Improves 5-Year Survival in Lung Cancer http://www.zacks.com/stock/news/423872/mercks-keytruda-improves-5-year-survival-in-lung-cancer?cid=CS-ZC-FT-423872 Jun 03, 2019 - Merck (MRK) presents longest follow-up data for Keytruda in advance lung cancer at ASCO 2019. The five-year overall survival rates in the Keytruda arm are better than historical rates

Pages: 1234

Page 1>